NephroGenex (NRX) Misses Q2 EPS by 16c

NephroGenex (NASDAQ: NRX) reported Q2 EPS of ($0.72), $0.16 worse than the analyst estimate of ($0.56).

For earnings history and earnings-related data on NephroGenex (NRX) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown